Vascular Intervention Strategies Trial for Alzheimer's

This study is looking at how managing blood pressure and cholesterol might help people at risk for dementia. It's a small pilot study with 10 participants, aged 50-75, who carry a specific gene (APOE ε4) linked to dementia risk. You would receive pharmacist-led care for six months. This care includes medication for high blood pressure, specifically Angiotensin Receptor Blockers (ARBs), and medication for high cholesterol, either Hydrophilic Statins or a non-statin alternative. The main goal is to see how well blood pressure is controlled during this six-month period. The study is currently unclear on its recruitment status.

Study design: This is an interventional pilot study with 10 participants. All participants will receive the same treatments.
What's involved: You would receive pharmacist-led management of your blood pressure and cholesterol over a six-month period.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, blood pressure control, is measured from the start of the study up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Vascular Intervention Strategies Trial for Alzheimer's

Not Yet Recruiting

PHASE2Ages 50–75InterventionalTreatment

University of Southern California

~10 participants

Updated 2026-05-04 on ClinicalTrials.gov

What's tested:Angiotensin Receptor Blockers (ARBs)Hydrophilic Statins or Non-Statin Alternative

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Blood Pressure Control

Measured over Baseline to 6 months

Conditions

Hypertension

Hypercholesterolemia

Dementia Risk Factors

Where it's being run

1 sites across 1 states

California1

Who to contact

Hussein Yassine, MD

[email protected]

(323) 442-0272

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

APOE ε4 carrier (homozygote or heterozygote)

LDL-C of 100-250 mg/dL

Systolic blood Pressure (SBP) 130-180 mm Hg

Age 50-75 years

Fluency in English

No dementia based on medical record review

Male or post-menopausal female

Exclusion

One minute standing SBP \< 110 mm Hg

Arm circumference prevents from accurate BP measurement with use of available devices

Lost weight of \> 10% unintendedly (within the past 6 months),

Contraindications to blood pressure and cholesterol lowering medications

Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)

Evidence of dementia based on medical record review

Living in a skilled nursing or rehabilitation facility

Receiving palliative or hospice care

Bipolar illness or schizophrenia

Drug or alcohol disorder

Receiving chronic opioid therapy

Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)

Severe loss of visual, hearing or communication ability

Organ transplant

History of stroke, symptomatic HF or left ventricular ejection fraction \< 35%

ESRD or eGFR \< 20 ml/min /1.73m2

Does not consent to be contacted or to have their medical record reviewed for research purposes

Concurrent participation in another clinical trial

What this trial measures

Blood Pressure ControlBaseline to 6 months
Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.

Trialytics